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Malignant Mixed Mullerian tumours (MMMTs) of the uterus account for 
1-2% of all endometrial malignancies and have been a problem, in terms of 
both subclassification and diagnosis for many years. The entity was first de-
scribed in 1864 by Virchow (92) who described -a mixed form of sarcoma and 
carcinoma of the uterus, but the first well documented uterine carcinosar-
coma was reported by Weber in 1867 (96), and again by Babl-Ruckhard in 
1872 (6). Between the early 1900s and 1950s most papers on the subject . 
consisted of single case reports with or without a review of the literature, 
which at that stage was still rather scanty and poorly understood. Tumours 
masqueraded under a variety of different names in an attempt to fit a name 
to the histologic pattern as well as trying to explain the histogenesis. The 
number of terms designated to this tumour entity became astronomical and 
included primary chondrosarcoma, adenoliposarcoma, sarcoma hydropicum 
polyposum uteri embryoides, dysontogenic tumour, mesenchymal sarcoma, 
carcinosarcoma, mixed tumour and malignant mixed mesodermal tumour. 
In 1935 McFarland (55), in a literature survey of utero-vaginal neoplasms 
with a list of 516 references, found 119 different names given to the entity. 
In 1941 Liebow and Tennant ( 45) attempted to summarise the anatomical 
and clinical data in these mixed uterine sarcomas. The diagnosis of malignant 
mixed tumour was based on the presence of heterologous elements such as 
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striated muscle, osteoid, cartilage and osteoid. The term carcinosarcoma 
was reserved for those tumours with epithelioid and spindle cell elements. 
Whether these were true biphasic tumours or carcinomas with spindle cell 
dedifferentiation was uncertain. 
There was much speculation as to the origin of these tumours. Many 
considered them to be malignant growths of metaplastic origin, while others 
considered the possibility that they might arise from benign tumours de-
veloping in heterotopic uterine tissue. However, because of the multiplicity 
of tissue types seen, most pathologists favoured the theory that the devel-
opment of these tumours came from a multipotential stem cell. Another 
viewpoint favoured atypical connections between embryonal and mesenchy-
mal cells from the inguinal area or misplaced ectopic rests as the primary 
site. 
In 1954, Sternberg (87), who believed these tumours to be of Mullerian 
duct origin, proposed that the term malignant Mullerian tumour be used. His 
studies indicated that this tumour arose from specialised mesodermal tissue 
and that the carcinomatous components were limited by the epithelial po-
tentialities of the Mullerian tract . Sa.rcoma.tous elements of these neoplasms 
were not rigidly limited in type by their Mullerian ancestry, and in com-
mon with mesenchymal cells elsewhere, retained the ability to differentiate 
into many mesenchymal derivations such as chondrosarcoma, fibrosarcoma, 
rhabdomyosarcoma and leiomyosarcoma. 
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Between 1950 and the mid 1970s several articles (16, 18, 39 , 45, 51 , 54, 
72, 79, 81, 87) appeared from various large institutions describing the range 
of morphologic findings, documenting the clinical disease, presentation, age 
range, mode of spread and modalities of therapy used. The majority of pa-
tients were postmenopausal women between the ages of 45-85 with a mean 
age of 65 years. The commonest presentation was that of postmenopausal 
bleeding, followed by lower abdominal pain/ discomfort and a pelvic mass. 
There was no significant association between this tumour and obesity, hyper-
tension or diabetes, and the role of prior radiotherapy as a possible aetiologic 
factor was controversial. Generally, the prognosis was poor. 
In 1966 Norris and Taylor (61) reviewed :n cases of carcinosarcoma and 
addressed the problem - "Is carcinosarcoma the same entity as mixed mes-
enchymal tumour?" Their findings showed that the 31 patients with carci-
nosarcoma had an overall better prognosis than those containing mixed or 
· heterologous elements, and recommended that the terms not be used inter-
changeably, but that they be regarded as separate entities because of their 
different behavioural patterns. In a follow up study ( 62) of 31 cases of heterol-
ogous mixed mesodermal tumours, they attempted to evaluate the relation-
ship of the morphologic features to the survival of the patients. The presence 
of cartilaginous elements was found to be associated with a more favourable 
prognosis, whereas the presence of rhabdomyoblastic cells indicated a worse 
prognosis. They emphasised, however, that the over.all prognosis of this 
3 
group was worse than carcinosarcoma. The authors also supported the view 
that the origin of these tumours was a multipotential stem cell which could 
differentiate along both carcinomatous and sarcomatous lines, and that the 
inherent metaplastic potential of the sarcomatous cells accounted for the 
wide variety of mesenchymal elements . Another clinicopathologic study of 
66 cases from the Netherlands (81), evaluated after 5 years of therapy, showed 
the same trend as found by Norris and Taylor with their carcinosarcomas, 
i.e. a mean 43, 7% five year survival and a mean 27% five year survival for 
the mixed mesodermal group. 
In contrast to this, studies of a large series of patients by Chuang et al 
(16) and later by Williamson and Christopherson (99), found that there was 
no significant difference in the biological behaviour of these two groups, i.e. 
carcinosarcoma and mixed mesodermal tumours, and hence no difference in 
prognosis. These tumours differed only in their histological appearance and 
not in their clinical course. The issue remained unresolved. 
In the following years various reputable institutions once again reported 
retrospective studies with follow up (22,57, 69,76,82). Little new informa-
tion was added to the clinical and pathologic findings, but issues revolved 
around modalities of therapy, in particular the "type of surgery". Discussion 
centered around the use of adjuvant chemotherapy and radiotherapy. It was 
recognised that this was an aggressive tumour, with a propensity to both vas-
cular and lymphatic invasion, and that an aggressive treatment programme 
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was warranted. Several series reported an improved survival in patients with 
stage I and II disease when chemotherapy was given prior to surgery and 
radiotherapy. 
Studies to determine the most important prognostic indicator were un-
dertaken by Barwick and Livolsi (8) who found that the most important 
factor was tumour extent, particularly the depth of myometrial invasion. 
Though their homologous group had a better 5 year survival rate than the 
heterologous counterpart, the true significance of heterologous elements was 
uncertain. Most believed that heterologous tumours were more aggressive 
because of a more rapid growth and, hence, deeper myometrial invasion and 
metastatic spread. The forty year experience of carcinosarcomas (homol-
ogous tumours) from the State of Missouri, reported by Doss et al (21), 
emphasised the need for accurate staging - even explorative laparotomy for 
definite staging to determine the optimal therapeutic modality. In 25% of 
cases the staging was altered by surgery, and clinical staging was thus con-
sidered inaccurate and inadequate for proper management. Accurate staging 
included surgical staging - total abdominal hysterectomy and bilateral sal-
pingoophorectomy plus diaphragmatic wipes and peritoneal washings. An 
in depth review by Peters and Neelam (69) on the prognostic indicators in 
103 stromal sarcomas, 4 7 homologous and 32 heterologous mesodermal tu-
mours showed beyond any statistical doubt that the strongest factor relating 
to poor outcome was depth of myometrial invasion. A further adverse trend 
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was noted in patients with a history of previous pelvic irradiation, advancing 
age and an increase in uterine size. These were not considered to be statisti-
cally significant. Neither the presence of heterologous elements, nor cervical 
involvement was found to add any adverse prognostic factor. Irrespective of 
the histologic type of endometrial sarcoma, there were no long term survivors 
with extrauterine disease at initial presentation. 
THE HISTOGENESIS 
Through all these years of study, pathologists and clinicians have had differ-
ing opinions, as to both the classification of uterine mesenchymal tumours 
and their histogenesis. Various theories of origin have been proposed - from 
embryonic cell rests of the Mullerian duct; from metaplasia of the endome-
trial interstitial cell; from a multipotential primitive mesenchymal cell of the 
endometrium. Many believed that the sarcomatous cells were really carci-
nomatous cells in an unusual growth form. Some denied the existence of 
tumours such as carcinosarcomas and believed all were collision tumours. In 
1959 Rubin (78) undertook to study these tumours in culture in an attempt 
to throw light on the vastly divergent views of many pathologists. His study 
using carcinosarcomas (homologous MMMTs) was the first described success 
at culturing these tumour cells. Important factors such as exudation, inflam-
mation, vascularity, tumour bed and host response, thought to influence the 
growth pattern, were all eliminated. Tissue culture revealed two distinct cell 
lines with no intermediate forms or transitional areas between carcinoma and 
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sarcoma. These observations lent support to the belief that carcinosarcomas 
were a distinct entity. 
In 1963 Vellios (91) delineated his histologic criteria for the diagnosis. He 
reported 9 cases of mixed Mullerian tumours in a series of uterine sarcomas 
and emphasised two points; firstly that these tumours were not as rare as 
initially thought, and adequate sampling was important. Secondly he reiter-
· • 
ated the point that the histogenesis was uncertain and the discussion revolved 
around the various theories of that time which included: (i) derivation from 
embryonic rests carried along the mesonephric duct; (ii) Pfanneil's concept 
of uterine mucosal metaplasia giving rise to these malignancies and (iii) the 
most popular theory - a multipotential stem cell within the Mullerian sys-
tem. However, the following questions were still unanswered: "Was this a (i) 
"collision tumour" with an admixture of two histogenetically distinct malig-
nant cells, (ii) "combination tumour" with both histologic elements arising 
from the same stem cell, or (iii) "composition tumour" that is an endometrial 
carcinoma with an atypical reactive stroma?" In 1981 Ishiwata et al (34) of 
Japan, using in vitro cultures of carcinosarcomas succeeded in culturing two 
distinct and separate cell lines with specific characteristics - an adenocarci-
noma line (HWUA-1, HWUA-2) and a sarcoma cell line (HWUS-1, HWUS-2, 
HWUS-la). This data suggested that carcinosarcomas are combination tu-
mours composed of 2 kinds of cells. In Rubin's study, the cultured cells died 
after 2 weeks, making long term cultivation unsuccessful. This study, with 
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the establishment of a long term cell culture line, will undoubtedly be of 
great use, not only in understanding the histogenesis, but also in assessment 
of efficacy of anti-cancer agents. 
ELECTRON MICROSCOPY 
The first electron microscopic (E.M.) findings were published by Silverberg 
in 1971 (84). The carcinomatous foci were ultrastructurally similar to pure 
endometrial adenocarcinomas and included findings such as an increased nu-
clear cytoplasmic ratio, large nucleoli, a general decrease in the number -and 
complexity of cytoplasmic organelles, decreased desmosomes, and blunting 
and disorganisation of microvilli. The ultrastructural characteristics of the 
stromal cells were quite different in appearance to the carcinoma c lls, and 
no transitional forms could be seen between these two. Transitional stages 
were seen between stromal cells and areas of other mesenchymal differen-
tiation such as chondrocytic or fibrocytic foci. He emphasised the striking 
appearance of small rounded vesicles in the stromal cells which appeared to 
be derived from the Golgi apparatus. In addition, mitochondria were well 
developed and numerous, a rather unexpected finding considering that in 
normal endometrial stromal cells in the proliferative phase these cells were 
poorly developed. In the late secretory phase they were more common. 
Boram et al (12) described the E.M. features of a mixed mesodermal 
tumour with a prominent pleomorphic rhabdomyosarcomatous component 
and showed a range of immature rhabdomyoblasts with barely discernible 
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cytoplasmic filaments, to classic pleomorphic rhabdomyoblasts with strap-
like cells , tadpole-like cells and spindled cells with myofibrils and centrally 
located Z-band material. 
Bocker and Stegner (11) m 1975 further expanded this field of ultra-
structural differentiation of rhabdomyoblasts. They highlighted the fact 
that it might be difficult to discern the less differentiated stages of rhab-
domyoblasts from primitive mesenchymal stromal cells on light microscopy. 
Electron microscopy was useful to determine the presence of heterologous el-
ements. This study also paid particular attention to the types of cytoplasmic 
filaments found in the various stages of rhabdomyoblastic differentiation -
from the undifferentiated mesenchymal cell or presumptive rhabdomyoblast 
to the electron microscopic "light" rhabdomyoblast with abundant interme-
diate filaments, to the more differentiated rhabdomyoblast with myofibrils. 
In addition the changes in 13 cases of homologous stromal sarcomas, 4 pure 
heterologous and 21 mixed heterologous tumours were documented. 
This study and other E.M. studies (2,10) have shown that the stromal 
cell of endometrial stromal sarcomas resembles that of the normal early pro-
liferative phase endometrial stromal cell. This cell type is also present in 
the group of mixed tumours and transitions to other heterologous tissues are 
demonstrated. A feature in all tumours was the distinct epithelial-stromal 
interface. Epithelial nests were also separated from the stromal cells and 
matrix by a continuous basal lamina, often thin and delicate, but at times 
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appearing as multiple layers. 
An ultrastructural and immunohistochemical analysis of MMMTs by 
Geisinger (28) showed similar electron microscopic findings to previous stud-
ies. Cells with intermediate filaments, mostly of stromal origin, corresponded 
to the cells staining with anti-vimentin antibody, but focal vimentin positiv-
ity was also noted in the epithelial component of 6 out of 11 cases. Auerbach 
and Livolsi ( 4) have stated that these special techniques increased the sensi-
tivity in detection of rhabdomyoblasts over routine H & E staining, and also 
added that the use of epithelial membrane antigen and cytokeratin was use-
ful in detecting carcinoma cells and differentiating the poorly differentiated 
areas from sarcoma. 
THE CLASSIFICATION 
The pathologic classification of uterine sarcomas has been the subject of 
much debate. Nowadays most researchers would agree on the distinction be-
tween pure sarcomas and those with both sarcomatous and carcinomatous 
elements. In 1959 Ober (65) proposed a classification which used the concepts 
initially introduced by Fenker in 1864 (65). The uterine mesenchymal sarco-
mas were subdivided into pure sarcomas (i.e. composed of one cell type only) 
and mixed (more than one cell type); and also whether they were homolo-
gous ( containing tissue elements indigenous to the uterus) or heterologous 
( containing tissues foreign to the normal uterus) (Table 1 ). 
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TABLE 1 A classification of uterine sarcomas - Ober 1959 
1. Leiomyosarcoma 
Arising in a leiomyoma 
Arising diffusely in the uterine wall 
2. Mesenchymal Sarcoma 
Pure - homologous 
Endometrial stromal sarcoma 
Stromatous endometriosis ( endolymphatic stromal myosis )t 
Sarcoma botryoides ( without heter. elements) 




Liposarcoma (not reported) 
Mixed - homologous 
Carcinosarcoma 
Adenocarcinoma plus stromal sarcoma 
Adenoacanthoma plus stromal sarcoma 
Squamous carcinoma plus stromal sarcoma 
Sarcoma botryoides plus neoplastic epithelium 
Mixed - heterologous 
Carcinosarcoma (plus heter. elements) 
Mixed mesenchymal sarcoma 
Stromal sarcoma (plus heter. elements) 
Two or more heter. elements without mesenchymal 
"myxomatous" stromal sarcoma 
Sarcoma botryoides (with heter. elements) 




Reticulum cell sarcoma 
Lymphosarcoma 
Leukemic infiltration 5. Unclassified sarcoma 
6. Metastatic sarcoma ( not reported) 
tThese tumours are not uniformly malignant. 
iLymphangiosarcoma has also been reported. 
heter. = heterologous 
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This classification was used by some and expanded on by others. In 1966 
Norris and Taylor (62) further subdivided pure endometrial stromal sarcomas 
into: 
i)the stromal nodule 
ii)low grade endometrial sarcomas 
iii)high grade endometrial sarcomas 
These classifications were never universally accepted, but were the most use-
ful and histogenetically correct. However, utilisation for routine diagnostic 
purposes showed it was more detailed than necessary, and in 1970 Kempson 
and Bari (39) published a classification which they considered readily appli-
cable to routine tissue diagnosis with good reproducibility (Table 2). This 
classification separated the sarcomas according to the number and types of 
recognisably different tissues present. Pure sarcomas contained only a single 
recognisable sarcomatous element, whereas mixed tumours contained more 
than one element. The term homologous was applied to those morpholog-
ically recognised as being of uterine origin, whereas heterologous contained 
elements not intrinsically of uterine origin. The malignant mixed Mullerian 
tumours (they prefered this term to mixed mesodermal tumour, as it reflected 
the histogenetic origin) contained both carcinomatous and sarcomatous el-
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ements. They emphasised the need for adequate sampling together with 
histochemical stains to find the diagnostic areas. However, a small group 
would remain too poorly differentiated/undifferentiated as to defy classifica-
tion, hence forcing them into group IV - the unclassified sarcomas. 
TABLE 2 Classification of uterine Sarcomas - Kempson and Bari 1970 
I Pure sarcomas 
A. Pure homologous 
1. Leiomyosarcoma 
2. Stromal sarcoma 
3. Endolymphatic stromal myosis 
4. Angiosarcoma 
5. Fibrosarcoma 
B. Pure heterologous 




II Mixed sarcomas 
A. Mixed homologous 
B. Mixed heterologous 
Mixed heterologous sarcomas with or without homologous 
elements 
III Malignant mixed Mullerian tumours (mixed mesodermal tumours) 
A. Malignant mixed Mullerian tumour, homologous type 
Carcinoma plus leiomyosarcoma, stromal sarcoma, 
or fibrosarcoma, or mixtures of these sarcomas 
B. Malignant mixed Mullerian tumour, heterologous type 
Carcinoma plus heterologous sarcoma with or without 
homologous sarcoma 
IV Sarcoma, unclassified 
V Malignant lymphoma 
13 
As an alternative, numerous institutions used the W.H.0. International 
classification of tumours released in 1975 (Table 3) , and though it was of 
value to numerous clinicians, pathologists found that many subsequently de-
fined categories, e.g. adenofibroma, adenosarcoma and endometrial stromal 
nodule, were not accounted for. Hence, many continued to follow the classi-
fication proposed by Kempson and Bari. In addition, recommendation was 
made to avoid all meaningless terminology such as sarcoma botyroides and 
even carcinosarcoma as the latter was often used for both homologous and 
heterologous tumours, and hence had lost its specificity. 
Hendrickson and Kempson (33) highlighted that four combinations of 
histologically benign and malignant tissue components are possible. 
1. Both stromal and epithelial components are malignant: malignant mixed 
Mullerian tumours. 
2. Both stroma and epithelial components are benign: Mullerian adenofi-
broma. 
3. The epithelium is benign and the stroma malignant: Mullerian adenosar-
coma. 
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4. The epithelium is malignant and the stroma is benign: e.g. carcinofi-
broma. This category is difficult to accept as a separate entity, as 
all adenocarcinomas with proliferating benign stroma would fall into 
this group. The stroma, however, is not considered part of the usual 
endometrial adenocarcinoma, except in rare conditions like carcinofi-
broma. 
Their classification, based on the above and incorporating a modification 
of Ober's original classification (including the benign mesenchymal tumours) 
is shown in Table 4. They have recommended the terms homologous and 
heterologous mixed malignant Mullerian tumour rather than carcinosarcoma 
and mixed mesodermal tumour. These terms are frequently used interchange-
ably and have led to confusion since it is often difficult to recall which term 
belongs to which tumour. Following the publication of their book (33), the 
classification has been used by most major academic institutions, both clin-
ically and pathologically, and is the classification used in this study. 
Earlier this year (1989) the International Society of Gynaecological Pathol-
ogists proposed a modified W.H.O. and F.I.G.O. classification (Table 5). 
Ironically the term carcinosarcoma has been reintroduced, qualified by the 
terms homologous and heterologous, and is used in preference to malignant 
mixed Mullerian/mesodermal tumour. 
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PURPOSE 
It is the purpose of this study to use immunohistochemistry (i) to docu-
ment the staining patterns seen in various tumours; (ii) to evaluate the use 
of these markers in delineating anaplastic and undifferentiated carcinoma-
tous from sarcomatous areas, and to assess whether these stains enhance 
the sensitivity of detecting heterologous elements; (iii) to elucidate whether 
immunocytochemistry contributes any further information regarding the his-
togenesis of these tumours. 
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TABLE 3 W.H.O. Classification of neoplasms of the uterine corpus 
-1975. 
I Epithelial Tumours and Related Lesions 
A. Benign 
1. Endometrial polyp 
2. Endometrial hyperplasia 
B. Atypical Endometrial Hyperplasia 
C. Malignant 
1. Adenocarcinoma 
2. Clear cell (mesonephroid) adenocarcinoma 
3. Squamous cell carcinoma 
4. Adenosquamous (mucoepidermoid) carcinoma 
5. Undifferentiated carcinoma 
II Non-epithelial Tumours 
A. Benign 
1. Leiomyoma (fibromyoma) 
B. Malignant 
1. Leiomyosarcoma 
2. Endometrial stromal sarcoma 
III Miscellaneous Tumours 
A. Benign 
1. Adenomatoid tumour 
B. Malignant 
1. Mullerian mixed tumour 
(a) Carcinosarcoma 
(b) Mesodermal mixed tumour 
IV Secondary Tumours 
V Unclassified Tumours 
VI Trophoblastic Disease 
A. Syncytial "endometritis" 
B. Hydatidiform mole 
C. Invasive hydatidiform mole ( chorioadenoma destruens) 
D. Choriocarcinoma 
VII Tumour-like Conditions 
A. Squamous metaplasia 
B. Adenomyosis ( endometriosis interna) 
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TABLE 4 Classification of primary uterine mesenchymal neoplasms -
Hendrickson and Kempson 1980 
BE IGN NEOPLASMS 
I Lei om yo mas 
A. Morphologic variants 
B. Growth variants 
II Endometrial stromal nodule 
III Uterine tumours resembling ovarian sex cord tumours 
IV Lipoma 
V Hemangioma 
VI Mullerian adenofibroma (papillary adenofibroma) 
SARCOMAS 
I Pure sarcomas 
A. Pure homologous 
1. Leiomyosarcoma 
2. High grade endometrial stromal sarcomat 
3. Low grade endometrial stromal sarcoma 
( endolymphatic stromal myosis) 





II Mixed sarcomas - homologous or heterologous 
III Mixed M ullerian tumours 
A. Mullerian adenosarcoma 
1. Homologous type 
2. Heterologous type 
B. Malignant mixed Mullerian tumours 
1. Homologous type 
2. Heterologous type 
IV Sarcoma, unclassified 
V Malignant lymphoma 
tThe term "stromal sarcoma" without a qualifier refers to 
the high grade lesion. 
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TABLE 5 Uterine neoplasias : New I.S.G.P. proposed classification 
I Epithelial tumours and related lesions 
A. Hyperplasias 
B. Carcinoma, and the variants thereof 
II Non Epithelial Tumours 
A. Endometrial stromal tumours 
1. Stromal nodule 
2. Low grade stromal sarcoma 
3. High grade stromal sarcoma 
B. Smooth Muscle Tumours 
1. Leiomyoma and its variants 
2. Smoothe mus.de tumour of uncertain malignant potential 
3. Leiomyosarcoma 
C. Mesothelial Tumours 
D. Other Non epithelial Tumours 
1. Benign soft tissue 
2. Malignant soft tissue (pure heterologous) 
3. Mixed endometrial stromal and smooth muscle type 






1. Adenosarcoma - homologous - heterologous 
2. Carcinosarcoma (MMMT) - homologous - heterologous 
3. Carcinofibroma 
IV Miscellaneous Tumours 
V Secondary Tumours 
VI Unclassifiable Tumours 
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MATERIALS AND METHOD 
All endometrial lesions diagnosed as primary malignancies from the records 
of the Department of Anatomical Pathology, University of Cape Town, from 
1971 to 1987 inclusive were reviewed by light microscopy. Tissues had been 
fixed in 10% buffered formalin and were paraffin embedded. All blocks were 
recut at 3 µm thickness, and stained with haematoxylin and eosin. All cases 
had a mucicarmine and Periodic Acid Schiff stain to determine the presence 
of intracellular mucin. A silver stain for reticulin was used to delineate the 
growth pattern. In those cases where there was histologic suspicion of het-
erologous differentiation, further stains were done, such as Phosphotungstic 
acid haematoxylin to detect rhabdomyoblastic cross striations (indicative of 
rhabdomyoblastic differentiation) and Picrosirius Red stains for osteoid. 
On the basis of these stains the tumours were classified into specific di-
agnostic groups as follows: 
• Epithelial: adenocarcinoma, well, moderately and poorly differentiated 
with or without their metaplastic changes; uterine papillary serous car-
cinoma, mucinous carcinoma, clear cell carcinoma and undifferentiated 
carcmoma. 
• Pure Sarcomas: endometrial stromal nodule, low and high grade stro-
mal sarcomas, 
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• Mixed tumours: adenofibroma, adenosarcoma and malignant mixed 
Mullerian tumours (homologous and heterologous subtypes). 
lmmunohistochemical studies included cytokeratin, epithelial membrane 
antigen, desmin, vimentin, muramidase on the undifferentiated carcinomas, 
adenosarcomas,stromal sarcomas and MMMTs. CAM 5.2, alpha-1-antitrypsin, 
myoglobin, and S100 were done on a selected number of cases. Sections of 
endometrium from surgical hysterectomy specimens were used as normal con-
trols and included 9 proliferative, 8 early and mid-secretory, 4 late secretory 
and 9 atrophic states of endometria (total n=30). 
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ANTIBODIES USED: 
Antibody Clonality Supplier 
1. Cytokeratin Mono- Dakopatts 
Denmark 
2. Epithelial Mono - " 
membrane 
antigen 
3. Desmin Mono - " 
4. Vimentin Mono- " 
5. SlOO Poly- Dako 
Santa Barbara USA 
6. Myoglobin Poly- " 
7. Muramidase Poly- Dakopatts 
Denmark 
8. Alpha-1- Poly - " 
anti trypsin 
9. CAM 5.2 Mono - University College 
Hospital , London 
The four immunohistochemical primary monoclonal antibodies - cytok-
eratin, epithelial membrane antigen, desmin and vimentin - were obtained 
commercially from Dakopatts, Glastrop, Denmark, as were the polyclonal 
antibodies muramidase and alpha-1-antitrypsin. 
S100 and myoglobin are both polyclonal antibodies commercially avail-
able as prepacked prediluted kits from Dako (Dako Santa Barbara, CA, USA) 
as the DakoPapKit , system 40 for S100a protein and DakoPapKit system 
K520 for myoglobin. Method performed as per instructions. 
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CAM 5.2 (synthesised by Makin and Bobrow) was obtained from the 
University College Hospital London Medical School. This product is now 
also commercially available from Becton Dickinson. 
For immunohistochemical studies, 3 µm sections were deparaffinised and 
rehydrated using solutions of 96% and 70% alcohol, followed by distilled 
water. Tissue sections were stained using the 2 step indirect conjugate per-
oxidase anti-peroxidase (PAP) method as follows. Sections were trypsinised 
using a Sigma product Porcine pancreas type II trypsin. Trypsin (0,2g) plus 
Calcium chloride (0,2g) was made up in 200 ml of distilled water at 37°C. 
The solution was left to stand for 15 mins. before use, and used between the 
period 15-60 mins. for optimal and most stable activity of trypsin. Trypsin 
times for each monoclonal antibody were: cytokeratin and EMA 20 mins., 
desmin 12 mins. and CAM 5.2 for 10 mins. The polyclonal antibodies, alpha-
1-antitrypsin, muramidase, myoglobin and SlOO were trypsinised for 12 mins. 
All tissues were trypsinised at 37°C. Vimentin required no prior trypsinisa-
tion. 
Tissues were then inactivated by washing with cold water, followed by 
washing with 3% hydrogen peroxide in water for 5 mins. to block endoge-
nous peroxidase. To enhance antigenic sensitivity and decrease background 
staining, tissue sections were washed in a 1:25 dilution of non immune rabbit 
serum for 10 mins., drained, and the primary antibody layered on. These 
primary antibodies were diluted in phosphate buffered saline (PBS) at pH 
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7.6 as follows: vimentin, CAM 5.2, cytokeratin and EMA 1:10; desmin 1:50; 
muramidase 1:100 and alpha-1-antitrypsin 1:200. 
Slides were incubated at room temperature for 2 hours, then rinsed with 
PBS, the secondary linking antibody (i.e. the PAP conjugate) layered on, 
(1:25 dilution is made up in PBS and normal human serum to enhance chro-
mogenicity of the substrate), incubated at room temperature for 30 mins., 
washed with PBS and the substrate added. The substrate used for all an-
tibodies, except muramidase and alpha-1-antitrypsin was 3-amino-9-ethyl-
carbazole. After 40 mins. the reaction time was stopped by rinsing the 
sections with distilled water. Sections were counterstained using Mayer's 
haematoxylin and mounted in glycergel. 
The polyclonal antibodies muramidase and alpha-1-antitrypsin were com-
mercially obtained (Dakopatts, Glostrup, Denmark). A method similar to 
that used for the monoclonal antibodies was followed with some modifica-
tions. The secondary linking antibody was diluted to a 1:25 solution, and 
the chromogenic substrate diaminobenzidine-tetrahydrochloride was used. 
Positive tissue controls included normal endometrium and skin for cyto-
keratin and EMA, myometrium for desmin and vimentin; pulmonary macro-
phages for muramidase and alpha-1-antitrypsin; and a malignant melanoma 
for SlOO. Control tissues were selected with approximately the same length 




In the period under review (1971-1987) there were 461 cases originally di-
agnosed as primary endometrial malignancies. These were re-examined and 
classified on the basis of the light microscopic findings on H & E stain, to-
gether with the following special stains - Periodic acid Schiff with and with-
out diastase, mucicarmine, Bests's carmine and reticulin. The results are 
tabulated below (Table 6). 
total case 
Diagnosis No % 
1 Severe atypical hyperplasia 8 1.7 
2 Adenocarcinoma 324 70.2 
3 Uterine papillary serous carcinoma 18 3.9 
4 Clear cell Ca 5 1.1 
5 Undifferentiated Ca 24 5.2 
6 Adenosarcoma 6 1.3 
7 Stromal sarcoma 16 3.4 
8 MMMT 58 12.5 
9 Miscellaneous i.e. unclassifiable 2 0.4 
TOTAL 461 
One miscellaneous case histologically resembled a lymphoma, and the 
other a sarcoma. The undifferentiated carcinomas, adenosarcomas, stromal 
sarcomas, unclassifiable tumours and MMMTs formed the basis of further 
immunohistochemical study - this totalled 106 cases. 
Twenty five of these 106 cases were excluded (Table 7) because either (i) 
the material was too degenerate and necrotic for immunohistochemistry, (ii) 
no tissue remained in the block, (iii) blocks were not available. This left 81 
cases available for further study. 
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TABLE 7 Distribution of final cases 
No. of cases excluded Final No. 
Undiff. Ca 6 18 
AdenoSA 1 5 
Stromal SA 5 11 
MMMT 13 45 
Unclassified 0 2 
TOTAL 81 
The mean age of all patients was 58,5 years ranging from 14 - 87. The 
mean age and age range for each diagnosis is tabulated below (Table 8). 
TABLE 8 The age distribution 
Diagnosis mean age age range 
Undiff.CA 63 52 - 87 
AdenoSA 46 14 - 82 
Stromal SA 59 44 - 82 
MMMT 66 47 - 86 
All except 5 patients were postmenopausal and presented with post-
menopausal bleeding and/or a pelvic mass. Two patients, aged 14 and 21, 
both with adenosarcomas presented with irregular menses and a pelvic mass. 
Of the remaining three cases, one presented with a pelvic mass and two with 
menorrhagia. 
Routine light microscopy showed that the undifferentiated carcmomas 
were composed of sheets of u~differentiated cells, no evidence of glandular 
differentiation or mucin positivity, and a packeted pattern on reticulin stains 
in 50% of cases. The adenosarcomas, 2 of which showed heterologous rhab-
doid elements, and stromal sarcomas showed histologic features as described 
in the literature. The majority (68%) of MMMTs showed a fairly even dis-
tribution of both carcinomatous and sarcomatous elements. In 12 cases the 
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stroma was in excess of the epithelial component, and in 7 the carcinomatous 
component predominated. The malignant epithelial components of MMMT 
varied from undifferentiated carcinoma to moderate to well differentiated ade-
nocarcinoma (Fig. 1). Striking tubulo-glandular patterns and classic serous 
papillary type growth patterns were noted in 9 cases (Fig. 2). Squamous 
metaplasia was noted in 8 cases. Of the 45 MMMTs 26 were homologous 
and 19 heterologous tumours. The homologous stromal cells showed vary-
ing cytology. The majority of cells were stellate or spindled, but some were 
more plump and rounded (Fig. 3). Bizarre multinucleate cells with hyper-
chromatic nuclei were present in several homologous MMMTs, but were not 
arranged in a storiform pattern to justify the diagnosis of MFH (Fig. 4). In 
20% of cases these cells also contained intracytoplasmic eosinophilic glob-
ules resembling effete red blood cells and were present in both homologous 
and heterologous tumours (Fig. 5). There was no consistent staining pat-
. tern of these globules when stained with PAS and PTAH. On H & E, 4 of 
the homologous MMMTs showed rhabdoid-like cells, only 2 of which were 
subsequently reclassified as heterologous because of strong desmin positivity 
(Fig. 6). There was no further evidence by PTAH and myoglobin stains to 
substantiate that the other 2 were of rhabdoid origin. Of the heterologous 
MMMTs 53% (n=lO) showed rhabdomyoblastic differentiation (Fig. 7), 36% 
(n=7) chondrosarcomatous change (Fig. 8), 20% (n=4) showed areas resem-
bling osteosarcoma (Fig. 9) and 20% (n=4) showed features consistent with 
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Malignant Fibrous Histiocytoma (Fig. 4). 
Immunoperoxidase stains were recorded as being negative; focally pos-
itive and strongly positive - the latter two grouped together as positive. 
The tissue sections used as positive controls for the monoclonal/polyclonal 
antibodies were all strongly positive. 
Control specimens 
Thirty endometrial samples from 9 proliferative, 8 early and mid-secretory, 4 
late secretory and 9 atrophic endometria were analysed. EMA, CK, desmin, 
vimentin and muramidase were performed on all cases, the results of which 
are displayed below (Table 9 and Fig. 10). 
TABLE 9 Results of control endometria 
No. of positive cases 
Endometrium EMA CK DES VIM MURAM 
Proliferative (n=9) G 8 5 0 8 0 
s 0 0 0 9 0 
Secretory - early /mid (n=8) G 6 6 0 4 0 
s 0 0 0 8 0 
- late (n=4) G 4 2 0 3 0 
s 0 0 0 4 0 
Atrophic (n=9) G 9 3 0 5 0 
s 0 0 0 9 0 
G = glands; S = stroma 
Those cases in which cytokeratin and/or EMA were negative or weakly 
positive, were subjected to further staining with CAM 5.2. All were strongly 
positive for this low molecular weight cytokeratin (Table 10). 
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TAB LE 10 Results (';AM .~.2 control endom etria 
CAM 5.2 positivity 
Endometri um Positive 
Proliferative (n=3) 3 
Secretory - early /mid (n=2) 2 
- late (n=2) 2 
Atrophic (n=6) 6 
In all cases, at least one of the epithelial markers was positive and only 
the epithelial elements stained positively for EMA, cytokeratin and/or CAM 
5.2. EMA intensity of staining was stronger than cytokeratin in the majority 
of cases (Fig. 10) and similarly, CAM 5.2 was of greater intensity than cy-
tokeratin in the cases where it was done. In all the control specimens of this 
study, both myometrial and vascular smooth muscle were present and there 
was no positive staining of these elements with CAM 5.2. The literature on 
CAM 5.2 states that there is cross reactivity with this low molecular weight 
cytokeratin and smooth muscle (13,27,64). 
Vimentin showed an interesting pattern of staining with both stromal 
and glands elements being positive in 20 of the control cases (Fig. 10), the 
remaining 10 showed positivity in the stromal elements only. Both epithelial 
and glandular staining were present in 8 proliferative, 4 early /mid secretory, 
3 late and 5 atrophic endometria. In all cases the epithelium was either equal 
to, or of slightly weaker staining intensity to the stromal element. No cases 
showed epithelial staining predominating over the stromal intensity. 
All cases were negative for desmin and muramidase. 
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Immunoperoxidase stains for the test cases were also recorded as focally 
positive, strongly positive and negative (Table 11 ). After examination of the 
immunocytochemistry, some of the cases were reclassified. 
TABLE 11 Results of Immunocytochemistry 
Initial diagnosis No. of cases POSITIVE 
EMA CK VIMEN DESM MURAM 
Undiff. CA (N=18) 17 15 9 0 1 
Stromal SA (N=ll) 2 2 10 4 0 
AdenoSA (N=5) 5 4 5 2 0 
MMMT (N=45) 40 34 41 11 12 
Unclassifiable (N =2) 2 0 1 0 0 
Those cases where cytokeratin was negative or weakly positive were sub-
jected to immunocytochemistry with a low molecular weight cytokeratin -
CAM 5.2 (Table 12) . 
TABLE 12 Positive cases with CAM 5.2 
Diagnosis No. 
Undiff CA (n=6) 6 
Stromal SA (n=ll) 1 
AdenoSA (n=l) 1 
MMMT (n=lO) 8 
Unclassifiable (n=2) 1 
Epithelial membrane antigen (EMA) preparations demonstrated granular 
membrane staining in 17 of the 18 undifferentiated carcinomas. The staining 
patterns were recorded as negative, weak focal positivity, and strong or diffuse 
positivity (i.e. in numerous cells). One case was entirely negative; 2 showed 
focal positivity and the remaining 15 showed strong diffuse positivity. 
Two stromal sarcomas showed strong diffuse positivity. These 2 cases, 
together with subsequent cytokeratin and desmin results led to an alteration 
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of the initial diagnosis from stromal sarcoma to MMMT. The epithelial el-
ements were not evident on H & E staining. The remaining 9 cases were 
negative for EMA. The adenosarcomas showed positivity in the benign glan-
dular elements in all cases . Stromal or heterologous elements were negative. 
The MMMTs showed positivity in the adenocarcinomatous (Fig. 11), 
tubulo-papillary, papillary serous-like and undifferentiated carcinomatous ar-
eas (Fig. 13). Isolated positive epithelial cells within the stroma, difficult to 
identify on H & E, were also noted to be positive. There were 5 negative 
cases, 7 showed focal positivity, and 33 showed strong positivity. None of the 
obvious stromal or heterologous elements were positive. However, in 2 cases 
the spindle cell elements were positive for EMA and CK, and were there-
fore reclassified as undifferentiated carcinoma with spindle cell change. In 
the miscellaneous group 1 case, morphologically resembling lymphoma, was 
leucocyte common antigen negative, but showed EMA and CAM 5.2 posi-
tivity and was reclassified as undifferentiated carcinoma. The second case -
sarcoma NOS, showed strong EMA positivity. 
Cytokeratin and CAM 5.2. Cytokeratin stains showed diffuse cytoplasmic 
staining of the malignant epithelial component throughout 15 of the 18 un-
differentiated carcinomas, 3 being negative. Of this negative group 2 showed 
strong cytoplasmic staining with CAM 5.2, confirming the epithelial nature, 
and 1 had strong EMA positivity. In addition, 34 MMMTs showed posi-
tive staining of the adenocarcinomatous, papillary and poorly differentiated 
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carcinomatous elements. In most tumours the gland forming cells appeared 
more intensely staining than the squamous cells with CAM 5.2, though the 
reverse was true for cytokeratin. There was no demonstrable positivity in 
stromal or heterologous elements, although scattered groups and single cells 
of epithelial origin were detected much more easily with irnrnunocytochem-
istry than with the H & E (Fig. 12 and 13). Cytokeratin was negative in 11 
MMMTs, 6 of which were positive for EMA and CAM 5.2, and 4 of which 
were totally negative for all three epithelial markers. In all these 4 cases the 
tumour appeared undifferentiated and tended to have features on H & E and 
reticulin stain suggestive of epithelial heritage. Irnrnunocytochemistry was 
unable to prove this. 
The adenosarcomas showed cytokeratin positivity in the benign glandular 
elements of the tumour in 4 of 5 cases, the 1 negative case was strongly CAM 
5.2 positive. In all 5 cases the epithelial membrane antigen was positive. 
In 9 cases of stromal sarcomas the cytokeratin and CAM 5.2 were negative 
and 2 cases were positive for cytokeratin (1 showing strong diffuse positivity 
and the other weak focal positivity). The CAM 5.2 on the latter case was 
strongly positive. 
Vimentin staining demonstrated diffuse cytoplasmic granular positivity 
which was recorded as focal positivity, strongly positive, and negative. Of 
the undifferentiated carcinomas 8 were negative, 7 showed focal positivity 
in scattered groups of tumour cells, and 2 were strongly positive. A to-
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tal of 41 MMMTs showed positivity. The homologous stromal cells were 
vimentin positive in the rounded, spindled and stellate cells, though not all 
cells in a given neoplasm were positively stained. The staining pattern varied 
from diffuse intracytoplasmic granularity to dense block-like intracytoplas-
mic staining. Heterologous cells of rhabdomyoblastic, chondroid, MFR-like 
areas and osteosarcomatous differentiation also showed scattered cells to be 
positive. The epithelial element of MMMT showed positivity in both the well 
differentiated areas of adenocarcinoma and the less differentiated areas (Fig. 
13). The positivity was diffuse cytoplasmic and granular and was present in 
21 MMMTs. In these cases the intensity of staining was either equal to or 
less than the stromal staining, but never more. 
A totally negative staining pattern for vimentin was noted in 4 MMMTs, 
2 of these (see EMA and CK) subsequently turned out to be undifferentiated 
carcinomas. The other 2 clearly had a malignant stromal element, 1 with 
rhabdomyoblastic differentiation, but in both vimentin staining was consid-
ered to be negative. Stromal components of 5 adenosarcomas were strongly 
positive and 3 showed positivity in the benign glandular components as well. 
Stromal sarcomas were positive in 10 instances and negative in 1 - this 
latter case had its diagnosis altered to MMMT on the basis of EMA positivity. 
Of the 2 unclassifiable cases 1 was positive and 1 was negative. 
Desmin and Myoglobin showed strong cytoplasmic staining which was 
graded as positive or negative. No undifferentiated carcinoma was positive. 
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While 4 homologous MMMTs showed stromal cells with rhabdoid feature, 
only 2 were positive for desmin and were thus reclassified as heterologous 
MMMTs. The 1 homologous tumour where heterologous rhabdoid differen-
tiation was not detected on H & E initially, showed several strongly positive 
desmin staining cells, adding another heterologous MMMT. Of the initially 
diagnosed heterologous MMMTs, 9 showed obvious rhabdomyoblastic differ-
entiation, all staining positively with desmin, though the intensity of staining 
varied from cell to cell and tumour to tumour. · 
There was no desmin or myoglobin positivity in the remainder of the 
heterologous MMMTs where rhabdoid features were not present on H & E. 
Myoglobin was done on 11 cases, 2 of which were both desmin and myoglobin 
negative. In the remaining 9 cases only 3 showed definitive positivity, 6 
were either negative or equivocal. Polyclonal myoglobin does not appear to 
be a very sensitive or specific marker for rhabdomyoblastic differentiation 
- considerable non specific background staining was noted in several cases 
and cross reactivity with both epithelial and other stromal elements, viz. 
chondroid, was also noted in some cases. 
Muramidase. The same criteria as before were employed in interpretation 
of positivity and only granular cytoplasmic staining was considered positive. 
All except 1 undifferentiated carcinoma were negative. The exception stained 
positively in scattered tumour cells , but intensity was not strong. This un-
differentiated carcinoma was reclassified as a homologous MMMT on the 
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basis of imrnunocytochernistry. Weak positivity was present in 11 MMMTs 
but 1 case was strongly positive in the stromal cells, particularly the larger 
pleomorphic bizarre MFR-like cells. The adenosarcomas and stromal sarco-
mas were all negative, as well as 1 of the unclassifiable group. The second 
unclassifiable tumour showed patchy positivity and, together with other im-
munocytochemical stains, favoured a final diagnosis of MMMT. 
Alpha-1-antitrypsin was performed on 9 MMMTs which showed eosinophilic 
intracytoplasmic globules - 6 of these were positive for alpha-1-antitrypsin 
as well as for muramidase. The intensity of the globule staining varied from 
case to case. There was poor correlation between these MMMTs which were 
' positive for muramidase (n=ll) and alpha-1-antitrypsin, as only 1 of these 
was positive for both. 
The SlOO protein stain was done on all cases which showed chondroid 
differentiation (n=7) and all s~owed strong cytoplasmic and nuclear staining 
of the chondrocytic cells in this area. Features suggestive of neural differen-
tiation on H & E were noted in 1 tumour, but it was S100 negative. 
As a result of imrnunocytochemistry 11 of the 81 cases had their initial 
diagnosis changed. In all, 2 undifferentiated carcinomas, 2 stromal sarcomas 
and 2 heterologous MMMTs became homologous MMMTs; 2 homologous 
MMMTs and 1 unclassifiable tumour were recategorised as undifferentiated 
carcinomas; and 1 homologous MMMT and 1 unclassifiable tumour were 
recategorised as heterologous MMMTs (Table 13). 
35 
TABLE 13 Alteration of dia nosis after immunocytochemistry 
Initial diagnosis Final diagnosis 
Undiff. CA (n=18)--...... Undiff. CA (n=19) 
2 
Stromal SA (n=ll) _ 
2 
2 





Unclassifiable (n=2) ? 1 
AdenoSA (n=5) 
Stromal SA (n=9) 
homo. (n=28) MMMT 
heter. ( n=20) 
Unclassifiable (n=O) 
AdenoSA (n=5) 
The immunocytochemistry of all the final diagnoses are displayed below 
in Table 14. All the undifferentiated carcinomas expressed one dr more of 
the epithelial markers. The one case which was EMA negative did express 
both CK and CAM 2.5. Coexpression of vimentin was present in 37% of 
cases, and one epithelial tumour displayed weak muramidase positivity. This 
feature, though uncommon, is recognised in certain undifferentiated epithelial 
malignancies (89). 
Two stromal sarcomas showed myoid differentiation on H & E, confirmed 
by strong desmin positivity in numerous tumour cells. 
The heterologous elements of adenosarcomas consisted predominantly of 
rhabdomyoblasts and these cells were positive with desmin antibody staining. 
Adipose tissue and chondroid elements were also noted in one case. The 
spindled stromal cells were vimentin positive in all cases. 
Using a panel of epithelial markers, epithelial elements were present in all 
MMMTs - this is mandatory for the diagnosis. Interestingly, all epithelial 
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cells showed EMA positivity to varying intensity. The majority (93%) had 
vimentin positive stromal cells, and 27% showed stromal cells with histiocytic 
differentiation. 
TABLE 14 Immunocytochemistry of final diagnoses 
No. of positive cases 
Diagnoses EMA CK DES VIM MURAM 
Undiff. CA (n=19) 18 16 0 7 1 
Stromal SA (n=9) 0 0 3 9 0 
AdenoSA (n=5) 5 4 2 5 0 
MMMT (n=48) 48 35 13 45 13 
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DISCUSSION 
A diverse spectrum of histologic changes is displayed by Malignant Mixed 
Muller1an Tumours (MMMTs) of the uterus which are often a diagnostic 
challenge to the pathologist. The major differential diagnoses in homologous 
MMMTs where anaplastic epithelium or sarcomatous elements predominate 
are undifferentiated carcinoma and sarcoma respectively. Heterologous tu-
mours are more readily identified by the presence of malignant cartilage, bone 
.or striated muscle. Extensive sampling is mandatory to avoid misdiagnosis, 
but this study, as others (4,28,73), has shown that in a certain percentage 
(14% in this study) of cases the diagnosis cannot be made on H & E alone. 
Additional immunopathologic studies for identification of specific interme-
diate filaments (IFs) are required. These IFs are cytoskeletal components, 
which, once recognised by antibody staining techniques, are helpful in more 
accurate diagnosis and categorisation of tumours difficult to diagnose by con-
ventional means. In normal tissues IFs seem to be tissue type specific and 
~his cell type specific expression appears to be preserved when malignant 
change has taken place ( even in the most poorly .differentiated malignancies 
(73,89)). The four antibodies ( cytokeratin, CAM 5.2, desmin and vimentin) 
used in this study show a cell type specific expression that parallels the known 
embryonic pathways of differentiation. 
Cytokeratin (Dako Ck 1 monoclonal mouse anti-human cytokeratin) is 
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directed against human intermediate filaments keratin 18 and 6, but does 
not react significantly with keratins 1, 8 and 19 and other low molecular 
weight cytokeratins. 
CAM 5.2 (synthesised by Makin and Bobrow, University College Hospital 
Medical School, London; monoclonal mouse anti-human low molecular weight 
cytokeratin) reacts with one group B (basic) keratin of molecular weight 50 
kD, and two group A (acidic) keratins of molecular weights 43 kD and 39 
kD. These are the keratin types 8, 18 and 19 respectively. 
Desmin (Dako Desmin, monoclonal mouse anti-desmin) reacts with the 
intermediate filament protein desmin found in muscle cells by recognising an 
18 kD rod piece of the molecule. It stains both striated, smooth and cardiac 
muscle as well as tumours of myoid origin. 
Vimentin (Dako Vimentin monoclonal mouse anti-vimentin) reacts with 
the 57 dK intermediate filamentous protein present in cells of mesenchymal 
ongm. 
The other immunohistochemical markers include: Epithelial membrane 
Antigen (Dako EMA, monoclonal mouse anti-human epithelial membrane 
antigen) which reacts with a group of overlapping epitopes on several different 
molecules (related to milkfat globule protein) of molecular weight in the 
range 265 - 400 kD. These represent integral constituents on the surface cell 
membrane of epithelial cells. 
Muramidase (Dako, Lysozyme (Muramidase] polyclonal rabbit anti-human 
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muramidase) which reacts with cytoplasmic lysozymal enzymes is present in 
cells of myeloid, histiocytic-monocytic lineage, and in a few types of epithelial 
cells. This antibody is generally used in pinpointing the histiocytic nature 
of a cell proliferation, whether reactive or neoplastic. 
Alpha-1-antitypsin (Dakopatts, polyclonal rabbit anti-human alpha-1-
antitypsin) - this antibody, though primarily used as a histiocytic marker, 
. has been detected in a variety of epithelial cells and their tumours and also 
in germ cell tumours of yolk sac type. 
It was the purpose of this study to (i) document the staining patterns 
seen in various tumours; (ii) evaluate the use of these markers in delineating 
anaplastic and undifferentiated carcinomatous from sarcomatous areas and 
assess whether these stains enhanced the sensitivity of detecting heterologous 
elements; (iii) elucidate whether immunocytochemistry contributed to any 
further information regarding the histogenesis of these tumours. 
The documentation of the staining patterns has been recorded and tab-
ulated (Table 11, 12, 14). Because some elements are difficult to detect on 
H & E, the reclassification following immunohistochemistry is justified and 
Table 14 therefore shows the definitive staining patterns of this group of 
neoplasms which could be used for further study or diagnostic purposes. 
Unclassifiable mali gnancies leave clinicians in a difficult situation as re-
gards therapeutic options for the patient and, hence, every attempt should be 
made to pursue these cases further. The.epithelial markers were of particular 
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value in differentiating anaplastic undifferentiated carcinomas from sarcomas, 
and spindle cell squamous elements from true sarcomatous elements. Distinct 
epithelial markers were expressed in both unclassifiable cases - one showed 
focal aggregates of positivity interspersed with areas which were positive for 
mesenchymal markers only. The other showed a more diffuse staining pat-
tern. Because of this, a more accurate diagnosis of undifferentiated MMMT 
and carcinoma respectively, was made. 
All the epithelial markers proved to be of use. CAM 5.2 antibodies react-
ing with the low molecular weight cytokeratins, showed more intense staining 
than cytokeratin. In general it was also noted that EMA antibodies were 
more reliable than cytokeratin antibodies in the detection of epithelial ele-
ments in uterine tumours. This is in contrast to the findings in metastatic 
carcinomas or undifferentiated carcinomas from other sites. Due to a limited 
supply of the CAM 5.2 antibody, not all cases could be tested. In those 
tested (where CK/EMA was negative or weakly positive), the positivity was 
easily detectable and therefore CAM 5.2 seemed to be the most useful of 
these three markers in detecting carcinoma cells in this setting. As with 
all immunohistochemical analyses, a panel of antibodies is recommended to 
result in a broader specificity and greater sensitivity. The cost of the anti-
bodies is such that many small laboratories cannot afford a panel, and the 
MAK-6 is now recommended as the antibody with a wide specificity and high 
sensitivity. This antibody is not yet available in our laboratory, and we have 
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no experience with its use, but Listrom and Dalton ( 48) state the staining 
patterns and false positivity are very similar to CAM 5.2. 
The overall prognosis of homologous versus heterologous tumours is still 
controversial (14,52,69,84). This study has not incorporated the long term 
follow up of these cases and therefore, until more long term multicentre stud-
ies are done to accurately determine the influence of heterologous elements 
on prognosis, pathologists should attempt to record as accurately as possible 
the histologic changes. Detection of heterologous elements may be difficult 
and, as this study shows, one cannot rely on H & E criteria alone. Rhabdoid 
cells are often missed on H & E but are easily detected using anti-desmin 
antibodies with or without myoglobin. Detection of other heterologous ele-
ments by immunohistochemistry is not always as useful. Staining for SlOO 
protein provided little further useful diagnostic information and was posi-
tive only in those areas where chondroblastic differentiation was seen ( 4). 
Some cartilaginous foci were also vimentin positive. Neuroectodermal tissue 
staining positively for SlOO, has been described as a heterologous element in 
MMMT (29). 
Those areas which resembled malignant fibrous histiocytoma showed vari-
able stai_ning with muramidase. True histiocytic differentiation is best de-
tected using a panel of antibodies such as muramidase, alpha-1-antitrypsin, 
alpha-1-antichymotrypsin, MAC 387, Leu Ml and Leu M2. Muramidase per 
se did not reveal significant histiocytic differentiation, and MFH-like areas 
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were only seen in 20% of cases. Scattered bizarre multinucleate hyperchro-
matic cells were more common, but these too, showed a very variable staining 
pattern with muramidase from negative to strongly positive. There was no 
associated tissue histiocytic inflammatory response to the tumour in any of 
the cases studied. 
"Does the presence of MFH or muramidase positive histiocytes constitute 
a heterologous element?" - this question has seldom been addressed. In this 
study, the control endometria did not demonstrate any muramidase positive 
histiocytic cells, but then only a single antibody was used. Morris, Edwards 
et al (58) in an immunohistologic study on normal endometria showed that 
endometrial lymphoid tissue had many of the hallmarks of mucosal associ-
ated lymphoid tissue. Stromal histiocytes/macrophages were demonstrated 
(OKTMl and HLA-DR positive) dispersed around the basal giands. These 
findings were only noted in adult, and not in infant uteri. The histiocytes 
are thus acquired with age, together with the lymphoreticular system, and 
are not autochthonous to the endometrium. Because of this, they should be 
considered as heterologous elements. 
The intracytoplasmic globules often seen in these bizarre multinucleate 
cells were stained with PTAH, PAS with and without diastase in addition 
to muramidase and alpha-1-antitrypsin, but no consistent finding was noted. 
The most likely explanation for these globules is that they are macrolyso-
somes, but may indicate a degenerative cellular change. 
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The endometrial control specimens have shown that the epithelial markers 
are confined to the epithelial elements, whereas vimentin, originally thought 
to characterise only mesenchymal cells, was present in the glandular element 
in 66% of cases. Glandular positivity was seen in all phases of the endome-
trial menstrual cycle. Coexpression of vimentin by epithelial cells has been 
described (19,26,30) and hence IFs expression may vary at different stages 
/ 
. of embryonic development. The uterus and fallopian tube develop from the 
Mullerian system which originates from coelomic cavity. Studies on mesothe-
lial tissue by Czernobilsky et al (19) show that these cells may express both 
cytokeratin and vimentin. Studies on the mesothelium of the pleural cavity 
by Gosh and Gatter (30) and CJ Uys (personal communication) also show 
coexpression of vimentin and cytokeratin. It is therefore not surprising that 
these tumours, with a common ancestry, express more than one intermediate 
filament. 
If, however, epithelial cells only express epithelial markers, and stromal 
cells only express mesenchymal markers, then how does this help our under-
standing of the histogenesis of MMMTs? If it is true that neoplastic tumour 
cells carry through the intermediate filament expression from their parent 
cell, then all cells whi ch are negative for the epithelial markers must be of 
stromal or of another origin; and all cells which are positive for epithelial 
markers must be of epithelial origin. This then, would favour MMMTs to be 
of mixed lineage, i.e. of two cell types, a concept favoured in earlier times, 
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but which is no longer popular. 
An alternative explanation is that of neometaplasia. Metaplastic carcino-
mas have been well described in the breast, lung, pancreas and oesophagus. 
Malignant cells contain the genetic material which code for all the IFs. These 
cells, with unstable DNA nuclear material and loss of the normal DNA/DNA 
and DNA/RNA regulatory mechanisms may undergo changes such that they 
alter their IF expression and therefore they may gain, lose, or express more 
than one IF. If this is true, then immunocytochemistry is of little value in 
elucidating the histogenesis of these tumours. 
Finally, the origin of MMMTs may be from a single primitive multipo-
tential stem cell. The "multipotential stem cell" theory has always been a 
convenient one as it explains both the differentiation into carcinomatous and 
sarcomatous elements as well as the plethora of histologic findings; yet it 
assumes a monoclonal proliferation. Naturally, the primitive stem cell pos-
sesses the intrinsic genetic material to code for all the cytoskeletal filaments 
and expression may therefore vary from one tumour cell to another. Given 
these restrictions, immunocytochemistry is unlikely to be of great value in 
determining the histogenesis. 
CONCLUSION 
This study has reviewed 81 cases of undifferentiated carcinoma, stromal sar-
coma, adenosarcoma and Malignant Mixed Mullerian tumours. The immuno-
histochemical findings have been documented, and the value of immunologic 
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studies emphasised in accurately evaluating the precise nature of the lesion 
and the detection of heterologous elements. These are important both to 
the pathologist and to the clinician, if accurate classification and adequate 
clin_ical management are aimed for. The role of immunohistochemistry in 




Figure la (above) and 1 b (below) showing areas of moderately differentiated 
carcinoma interspersed with sarcomatous areas - the diagnosis of MMMT 
was made on both cases. (H & E, x 200) 
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Figure 2 shows an area of serous papillary differentiation in the carcinomatous 
element of a MMMT. (H & E, x 150) 
Figure 3 demonstrates the range of stromal cells in MMMT; spindled, stellate 
and rounded. (H & E, x 400) · 
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Figure 4: Multinucleate and bizarre hyperchromatic cells. 
Figure 4a shows an ill-defined storiform pattern with scattered multinucleate 
cells - resembling MFH. (H & E, x 400) 
Figure 4b shows scattered hyperchromatic cells and a storiform pattern is 
not evident. (H & E, x 400) 
50 
Figure 4c and 4d show bizarre multinucleate and hyperchromatic 'Stromal 
cells. (H & E, x 1600) 
51 
Figure 5 : Intracytoplasmic globules 
Figure 5a showing intracytoplasrnic globules in the strornal cells, of varying 
sizes. (H & E, x 400) 
Figure 5b: shows a high power magnification. (H & E, x 1600) 
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Rhabdoid stromal cells 
Figure 6a: showing rhabdomyoblastic differentiation of stromal cells on H & 
E staining (x 400). 
Desmin 
Figure 6b confirms this with strong desmin positivity in these cells. (Desmin, 
X 400) 
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Figure 7 : Rhabdomyoblasts 
Figure 7a: (H & E, x 1600) staining spindled eosinophilic rhabdomyoblasts, 
which stain strongly positive -with anti-desmin antibody in Figure 7b (below). 
(Desmin, x 1600) 
Desmin 
54 
Figure 7c shows rhabdomyoblasts, the central one demonstrating cross stri-
ations. (H & E, x 1600) 
55 
Figure 8: Chrondrosarcomatous Foci. 
Figure 8a (H & E, x 400) and Figure 8b (H & E, x 200) showing foci of 
chondroid differentiation. 
56 
Figure 8c showing a focus of chondro1d differentiation. (H & E, x 400) 
Figure 8d showing another chondrosarcomatous focus with malignant chon-
droid cells in lacunar spaces. (H & E, x 200) 
57 
Figure 9 Osteosarcomatous Differentiation 
Figure 9a (above) and Figure 9b (below) showing foci of fine interlacing 
osteoid interspersed between malignant stromal cells. (H & E, ?C 400) 
, _, . , . 
,I 
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Figure 10: Control Endometrium 
Figure 10a: Normal prolifera,tive endometrium. (H & E, x 400) 
EMA • 
• 
Figure 10b: The above case showing glandular staining with epithelial mem-
brane antigen. (EMA, x 400) 
59 
CK • 






Figure 10c demonstrating Cytokeratin positivity m normal endometrium. 
(CK, x 400) 
Figure 10d demonstrating Vimentin positivity in both the glands and stroma . . 
(Vimentin, x 400) 
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Vimentin 
Figure lOe shows a high power magnification of virnentin positivity~in both 
stromal and glandular elements. (Vimentin, x 1600) 
61 
Figure 11a: Homologous MMMT showing areas of poorly differentiated ade-
nocarcinoma. (H & E, x 400) 
EMA 
Figure 11 b shows EMA positivity in some of the glandular areas. (EMA, x 
400) 
62 
Figure 12: Homologous MMMT 
Figure 12a showing an ill-defined aggregate (arrow) of undifferentiated car-
cinomatous cells. (H & E, x 400) 
EMA 




Figure 12c showing cytokeratin positivity m the carcinomatous element. 
(CK, x 400) 
Figure 12d shows vimentin positivity in both stromal and epithelial compo-
nents. (Vimentin, x 400) 
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Figure 13 : Case Illustration of a Typical MMMT 
Figure 13a demonstrates a typical MMMT with plump eosinophilic stromal 
cells. (H & E, x 400) 
Vim. 




Figure 13c shows a different area of the same tumour where Vimentin staining 
is more pronounced. (Vimentin, x 200) 
CK 
Figure 13d shows glandular elements staining positively with cytokeratin and 
scattered free-lying carcinoma cells. ( Cytokeratin, x 400) 
66 
CK 
Figure 13e demonstrating Cytokeratin positivity in this tumour. (Cytoker-
atin, x 400) 
EMA 
Figure 13f shows strong epithelial membrane antigen positivity in the same 




Figure 13g demonstrates the strong membrane staining in another area of 
the same tumour. (EMA, x 400) 
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